Skip to content
EMUC25 special: Dr. Rescigno talks about single agent TKI in selected mRCC patients episode artwork

EPISODE · Nov 18, 2025 · 8 MIN

EMUC25 special: Dr. Rescigno talks about single agent TKI in selected mRCC patients

from EAU Podcast · host European Association of Urology

UROONCO RCC associate editor Assoc. Prof. Carlotta Palumbo (IT) talks with medical oncologist Dr. Pasquale Rescigno (GB) about his presentation supporting the 'yes' position in the debate at EMUC25: “Is single agent TKI (tyrosine kinase inhibitor) still an option in selected mRCC patients? This interview was recorded at EMUC25 in Prague. For more updates on kidney cancer, please visit our educational platform UROONCO RCC. For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Episode metadata supplied by the publisher feed · Published Nov 18, 2025

Embed this episode

Ready to play

EMUC25 special: Dr. Rescigno talks about single agent TKI in selected mRCC patients

0:00 8:14

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of EAU Podcast?

This episode is 8 minutes long.

When was this EAU Podcast episode published?

This episode was published on November 18, 2025.

Can I download this EAU Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!